Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Curaleaf Holdings's Enterprise Value for the quarter that ended in Jun. 2026 was C$5,196 Mil.
Curaleaf Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curaleaf Holdings EV-to-EBIT Related Terms
Curaleaf Holdings EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Curaleaf Holdings's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Curaleaf Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curaleaf Holdings EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curaleaf Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Curaleaf Holdings's EV-to-EBIT falls into.
Curaleaf Holdings's current Enterprise Value is C$4,686 Mil.
Curaleaf Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curaleaf Holdings (TSX:CURA) has a EV-to-EBIT of 474.49 as of Aug. 07, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Curaleaf Holdings and its competitors. According to the industry distribution chart, Curaleaf Holdings ranks #677 out of 686 companies in the Drug Manufacturers industry, placing it in the top 98.7%.
Is Curaleaf Holdings' EV-to-EBIT too high?
Curaleaf Holdings' current EV-to-EBIT is 474.49. The Drug Manufacturers industry median EV-to-EBIT is 15.73. Curaleaf Holdings' value of 474.49 is 2917.4% above this industry median. Based on the distribution chart, Curaleaf Holdings ranks #677 out of 686 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Curaleaf Holdings has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Curaleaf Holdings' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Curaleaf Holdings ranks #677 out of 686 companies for EV-to-EBIT. This places Curaleaf Holdings in the lower half of its industry. The industry median EV-to-EBIT is 15.73. Curaleaf Holdings' value of 474.49 is 2917.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.73, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curaleaf Holdings's current EV-to-EBIT of 474.49 is 2917.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Curaleaf Holdings and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curaleaf Holdings's current EV-to-EBIT is 474.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curaleaf Holdings stock overvalued right now?
Based on GuruFocus' analysis, Curaleaf Holdings (TSX:CURA) is currently considered Modestly Overvalued. The stock's GF Value™ is C$11.56, compared to a current price of C$12.93 — trading 11.9% above its estimated fair value. The current EV-to-EBIT is 474.49 and 2917.4% above the Drug Manufacturers industry median of 15.73. Curaleaf Holdings' overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Curaleaf Holdings (TSX:CURA), the current EV-to-EBIT is 474.49 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Curaleaf Holdings (TSX:CURA) Overvalued in 2026?
Based on GuruFocus' analysis, Curaleaf Holdings stock appears to be overvalued.
The current stock price of C$12.93 is trading 11.9% above its estimated GF Value™ of C$11.56.
GuruFocus considers Curaleaf Holdings to be Modestly Overvalued.
Key valuation signals for TSX:CURA:
EV-to-EBIT: 474.49
GF Value™: C$11.56 vs. price of C$12.93 (11.9% above fair value)
Industry Position: 2917.4% above the Drug Manufacturers median (#677 of 686)
No single metric tells the full story. See the TSX:CURA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the US. The company has operations in 17 states. Its brands include Curaleaf, Select, and Grassroots. The company has made acquisitions that give it exposure to the growing European market, a unique feature among US multistate operators.
73GF Score
Get the complete analysis for TSX:CURA
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:CURA has been successfully added to your 
